Societal CDMO, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-12-20: Form 8-K; Period of report 2022-12-14; Description 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events; Details 2.01.
- 2022-12-13: Form 8-K; Period of report 2022-12-12; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.01.
- 2022-12-12: Form 8-K; Period of report 2022-12-09; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events; Details 1.01.
- 2022-11-16: Form 8-K; Period of report 2022-11-16; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-12-20 | 8-K | 2022-12-14 | 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events | 2.01 The information set forth in Item 8.01 is incorporated herein by reference. 8.01 As previously disclosed in a Current Report on Form 8-K filed by Societal CDMO, Inc. (the “Company”) on December 12, 2022 (the “Original 8-K”), on December 9, 2022, Societal CDMO Gainesville, LLC (“Societal Gainesville”), a wholly owned subsidiary of Societal CDMO Inc. (the “Company”), entered into a purchase and sale agreement (the “Purchase Agreement”) with Tenet Equity Funding SPE Gainesville, LLC (the “Purchaser”), a subsidiary of Tenet Equity L.P., pursuant to which Societal Gainesville agreed to sell certain real estate located at 1300 Gould Drive, Gainesville, Georgia 30504 (the “Property”) to the Purchaser for a purchase price of $39.0 million (the “Sale-Leaseback Transaction”). | sctl-20221214.htm |
| 2022-12-13 | 8-K | 2022-12-12 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 1.02 On December 13, 2022, the Company provided notice to Aspire Capital Fund, LLC (“Aspire”) of termination of that certain Common Stock Purchase Agreement, dated February 19, 2019, by and between the Company and Aspire, as amended (the “Aspire Agreement”), effective as of December 14, 2022. 5.03 On December 13, 2022, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the Commonwealth of Pennsylvania with respect to the Series A Stock. | d412844d8k.htm |
| 2022-12-12 | 8-K | 2022-12-09 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.01 The information set forth in Item 1.01 is incorporated herein by reference. 2.03 The information set forth in Item 1.01 is incorporated herein by reference. 8.01 Attached as Exhibit 99.1 is a presentation, including certain financial information, that the Company will use from time to time in presentations or discussions with investors, analysts, and/or other parties. | d426508d8k.htm |
| 2022-11-16 | 8-K | 2022-11-16 | 7.01 Regulation FD Disclosure | 7.01 Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on November 16, 2022 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | sctl-20221116.htm |
| 2022-11-09 | 8-K | 2022-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2022, Societal CDMO, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022. | sctl-20221109.htm |
| 2022-09-08 | 8-K | 2022-09-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 1, 2022, the board of directors (the “Board”) of Societal CDMO, Inc. (the “Company”) appointed Elena Cant to serve as a Class II member of the Board. | sctl-20220901.htm |
| 2022-08-22 | 8-K | 2022-08-18 | 8.01 Other Events | 8.01 As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 30, 2022, Societal CDMO, Inc. (the “Company”) received a deficiency letter on June 27, 2022 from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). | sctl-20220818.htm |
| 2022-08-16 | 8-K | 2022-08-11 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | sctl-20220811.htm |
| 2022-08-10 | 8-K | 2022-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2022, Societal CDMO, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2022. | sctl-20220810.htm |
| 2022-06-30 | 8-K | 2022-06-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 27, 2022, Societal CDMO, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). | sctl-20220627.htm |
| 2022-06-08 | 8-K | 2022-06-08 | 7.01 Regulation FD Disclosure | 7.01 Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on June 8, 2022 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | sctl-20220608.htm |
| 2022-05-20 | 8-K | 2022-05-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 18, 2022, Societal CDMO, Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”). | sctl-20220518.htm |
| 2022-05-11 | 8-K | 2022-05-11 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 11, 2022, Societal CDMO, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. 7.01 Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on May 11, 2022 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | sctl-20220511.htm |
| 2022-05-05 | 8-K | 2022-05-05 | 8.01 Other Events | 8.01 On May 5, 2022, Societal CDMO, Inc. issued a press release announcing that through its wholly owned subsidiary, Societal CDMO Gainesville, LLC (collectively, the “Company”), it had entered into a Commercial Manufacturing and Supply Agreement with InfectoPharm Arzneimittel und Consilium GmbH (“InfectoPharm”), pursuant to which the Company will be the exclusive supplier to InfectoPharm of Ritalin LA capsules in Europe through 2023. | d357121d8k.htm |
| 2022-03-21 | 8-K | 2022-03-15 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On March 15, 2022, Recro Pharma, Inc. (the “Company”) filed Articles of Amendment (the “Articles of Amendment”) to its Second Amended and Restated Certificate of Incorporation, as amended, with the Secretary of the Commonwealth of the Commonwealth of Pennsylvania to change the Company’s corporate name to Societal CDMO, Inc. (the “Name Change”). 8.01 On March 21, 2022, the Company issued a press release announcing the Name Change and that its ticker symbol on the Nasdaq Capital Market would change from “REPH” to “SCTL.” Trading under the new ticker symbol will begin on March 22, 2022. | d252566d8k.htm |
| 2022-03-01 | 8-K | 2022-03-01 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On March 1, 2022, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2021. 7.01 Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation that the Company will post on its website on March 1, 2022 and may use from time to time in presentations or discussions with investors, analysts, and other parties. | reph-20220301.htm |
| 2022-01-24 | 8-K | 2022-01-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 18, 2022, Gerri A. Henwood, a Class II member of the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”), notified the Company of her intent to resign from the Board, effective January 18, 2022. | reph-20220118.htm |
| 2022-01-14 | 8-K/A | 2021-08-10 | 9.01 Financial Statements and Exhibits | 9.01 (b) Pro Forma Financial Information. | reph-20210810.htm |